Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice

Kazuki Hatayama, Nobuyuki Nosaka, Mutsuko Yamada, Masato Yashiro, Yosuke Fujii, Hirokazu Tsukahara, Keyue Liu, Masahiro Nishibori, Akihiro Matsukawa, Tsuneo Morishima

Research output: Contribution to journalArticle

Abstract

Human pandemic H1N1 2009 influenza virus causes significant morbidity and mortality with severe acute lung injury due to the excessive inflammatory reaction, even with neuraminidase inhibitor use. The anti-inflammatory effect of anti-high-mobility group box-1 (HMGB1) monoclonal antibody (mAb) against influenza pneumonia has been reported. In this study, we evaluated the combined effect of anti-HMGB1 mAb and peramivir against pneumonia induced by influenza A (H1N1) virus in mice. Nine-week-old male C57BL/6 mice were inoculated with H1N1 and treated with intramuscularly administered peramivir at 2 and 3 days post-infection (dpi). The anti-HMGB1 mAb or a control mAb was administered at 2, 3, and 4 dpi. Survival rates were assessed, and lung lavage and pathological analyses were conducted at 5 and 7 dpi. The combination of peramivir with the anti-HMGB1 mAb significantly improved survival rate whereas the anti-HMGB1 mAb alone did not affect virus proliferation in the lungs. This combination therapy also significantly ameliorated histopathological changes, neutrophil infiltration, and macrophage aggregation by inhibiting HMGB1, inflammatory cytokines, and oxidative stress. Fluorescence immunostaining showed that the anti-HMGB1 mAb inhibited HMGB1 translocation from type I alveolar epithelial cells. In summary, combining anti-HMGB1 with conventional anti-influenza therapy might be useful against severe influenza virus infection.

Original languageEnglish
JournalJournal of Medical Virology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Influenza A virus
Pneumonia
Monoclonal Antibodies
Orthomyxoviridae
Human Influenza
Survival Rate
Infection
Alveolar Epithelial Cells
H1N1 Subtype Influenza A Virus
Neutrophil Infiltration
Acute Lung Injury
Neuraminidase
Bronchoalveolar Lavage
Pandemics
Virus Diseases
peramivir
Inbred C57BL Mouse
Oxidative Stress
Anti-Inflammatory Agents
Fluorescence

Keywords

  • acute lung injury (ALI)
  • cytokine
  • H1N1
  • oxidative stress
  • virus propagation

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice. / Hatayama, Kazuki; Nosaka, Nobuyuki; Yamada, Mutsuko; Yashiro, Masato; Fujii, Yosuke; Tsukahara, Hirokazu; Liu, Keyue; Nishibori, Masahiro; Matsukawa, Akihiro; Morishima, Tsuneo.

In: Journal of Medical Virology, 01.01.2018.

Research output: Contribution to journalArticle

@article{7ad399807d3546d396509dfd5f11f6ff,
title = "Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice",
abstract = "Human pandemic H1N1 2009 influenza virus causes significant morbidity and mortality with severe acute lung injury due to the excessive inflammatory reaction, even with neuraminidase inhibitor use. The anti-inflammatory effect of anti-high-mobility group box-1 (HMGB1) monoclonal antibody (mAb) against influenza pneumonia has been reported. In this study, we evaluated the combined effect of anti-HMGB1 mAb and peramivir against pneumonia induced by influenza A (H1N1) virus in mice. Nine-week-old male C57BL/6 mice were inoculated with H1N1 and treated with intramuscularly administered peramivir at 2 and 3 days post-infection (dpi). The anti-HMGB1 mAb or a control mAb was administered at 2, 3, and 4 dpi. Survival rates were assessed, and lung lavage and pathological analyses were conducted at 5 and 7 dpi. The combination of peramivir with the anti-HMGB1 mAb significantly improved survival rate whereas the anti-HMGB1 mAb alone did not affect virus proliferation in the lungs. This combination therapy also significantly ameliorated histopathological changes, neutrophil infiltration, and macrophage aggregation by inhibiting HMGB1, inflammatory cytokines, and oxidative stress. Fluorescence immunostaining showed that the anti-HMGB1 mAb inhibited HMGB1 translocation from type I alveolar epithelial cells. In summary, combining anti-HMGB1 with conventional anti-influenza therapy might be useful against severe influenza virus infection.",
keywords = "acute lung injury (ALI), cytokine, H1N1, oxidative stress, virus propagation",
author = "Kazuki Hatayama and Nobuyuki Nosaka and Mutsuko Yamada and Masato Yashiro and Yosuke Fujii and Hirokazu Tsukahara and Keyue Liu and Masahiro Nishibori and Akihiro Matsukawa and Tsuneo Morishima",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/jmv.25330",
language = "English",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice

AU - Hatayama, Kazuki

AU - Nosaka, Nobuyuki

AU - Yamada, Mutsuko

AU - Yashiro, Masato

AU - Fujii, Yosuke

AU - Tsukahara, Hirokazu

AU - Liu, Keyue

AU - Nishibori, Masahiro

AU - Matsukawa, Akihiro

AU - Morishima, Tsuneo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Human pandemic H1N1 2009 influenza virus causes significant morbidity and mortality with severe acute lung injury due to the excessive inflammatory reaction, even with neuraminidase inhibitor use. The anti-inflammatory effect of anti-high-mobility group box-1 (HMGB1) monoclonal antibody (mAb) against influenza pneumonia has been reported. In this study, we evaluated the combined effect of anti-HMGB1 mAb and peramivir against pneumonia induced by influenza A (H1N1) virus in mice. Nine-week-old male C57BL/6 mice were inoculated with H1N1 and treated with intramuscularly administered peramivir at 2 and 3 days post-infection (dpi). The anti-HMGB1 mAb or a control mAb was administered at 2, 3, and 4 dpi. Survival rates were assessed, and lung lavage and pathological analyses were conducted at 5 and 7 dpi. The combination of peramivir with the anti-HMGB1 mAb significantly improved survival rate whereas the anti-HMGB1 mAb alone did not affect virus proliferation in the lungs. This combination therapy also significantly ameliorated histopathological changes, neutrophil infiltration, and macrophage aggregation by inhibiting HMGB1, inflammatory cytokines, and oxidative stress. Fluorescence immunostaining showed that the anti-HMGB1 mAb inhibited HMGB1 translocation from type I alveolar epithelial cells. In summary, combining anti-HMGB1 with conventional anti-influenza therapy might be useful against severe influenza virus infection.

AB - Human pandemic H1N1 2009 influenza virus causes significant morbidity and mortality with severe acute lung injury due to the excessive inflammatory reaction, even with neuraminidase inhibitor use. The anti-inflammatory effect of anti-high-mobility group box-1 (HMGB1) monoclonal antibody (mAb) against influenza pneumonia has been reported. In this study, we evaluated the combined effect of anti-HMGB1 mAb and peramivir against pneumonia induced by influenza A (H1N1) virus in mice. Nine-week-old male C57BL/6 mice were inoculated with H1N1 and treated with intramuscularly administered peramivir at 2 and 3 days post-infection (dpi). The anti-HMGB1 mAb or a control mAb was administered at 2, 3, and 4 dpi. Survival rates were assessed, and lung lavage and pathological analyses were conducted at 5 and 7 dpi. The combination of peramivir with the anti-HMGB1 mAb significantly improved survival rate whereas the anti-HMGB1 mAb alone did not affect virus proliferation in the lungs. This combination therapy also significantly ameliorated histopathological changes, neutrophil infiltration, and macrophage aggregation by inhibiting HMGB1, inflammatory cytokines, and oxidative stress. Fluorescence immunostaining showed that the anti-HMGB1 mAb inhibited HMGB1 translocation from type I alveolar epithelial cells. In summary, combining anti-HMGB1 with conventional anti-influenza therapy might be useful against severe influenza virus infection.

KW - acute lung injury (ALI)

KW - cytokine

KW - H1N1

KW - oxidative stress

KW - virus propagation

UR - http://www.scopus.com/inward/record.url?scp=85055287621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055287621&partnerID=8YFLogxK

U2 - 10.1002/jmv.25330

DO - 10.1002/jmv.25330

M3 - Article

C2 - 30281823

AN - SCOPUS:85055287621

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

ER -